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Chemically induced dimerization of dihydrofolate reductase by a
homobifunctional dimer of methotrexate
Stephan J Kopytek1, Robert F Standaert2*, John CD Dyer1 and James C Hu1,3*
Background: Chemically induced dimerization (CID) can be used to manipulate
cellular regulatory pathways from signal transduction to transcription, and to
create model systems for study of the specific interactions between proteins
and small-molecule chemical ligands. However, few CID systems are currently
available. The properties of, and interactions between, Escherichia coli
dihydrofolate reductase (DHFR) and the ligand methotrexate (MTX) meet many
of the desired criteria for the development of a new CID system.
Results: BisMTX, a homobifunctional version of MTX, was synthesized and
tested for its ability to induce dimerization of DHFR. Gel-filtration analysis of
purified DHFR confirmed that, in vitro, the protein was a monomer in the
absence of dimerizer drug; in the presence of bisMTX, a complex of twice the
monomeric molecular weight was observed. Furthermore, the off-rate was found
to be 0.0002 s–1, ~100 times slower than that reported for DHFR–MTX .
Interestingly, the addition of excess bisMTX did not result in formation of the
binary complex (1 protein:1 dimerizer) over the ternary complex (2 proteins:1
dimerizer), which suggests cooperative binding interactions (affinity modulation)
between the two DHFR molecules in the bisMTX:DHFR2 ternary complex.
Conclusions: The combination of DHFR and bisMTX provides a new CID
system with properties that could be useful for applications in vivo. Formation of
the bisMTX:DHFR2 ternary complex in vitro is promoted over a wide range of
dimerizer concentrations, consistent with the idea that formation of the ternary
complex recruits energetically favorable interactions between the DHFR
monomers in the complex.
Introduction
Dimerization (or oligomerization) of proteins or protein
domains can be mediated by low molecular weight organic
compounds termed chemical inducers of dimerization or
‘dimerizers’ [1–6]. Several dimerizer systems have been
developed based on both natural products and completely
synthetic molecules [2,7–11] (Table 1). One of the original
chemically induced dimerization (CID) systems is based
on the immunosuppressive drug FK506 and the
immunophilin FK506-binding-protein 12 (FKBP).
Spencer et al. [2] synthesized FK1012, a homobifunctional
version of FK506, and used this semisynthetic dimerizer
to regulate signal transduction. By fusion of ζ, the intracel-
lular signaling domain of the T-cell receptor, to a protein
with drug-binding activity (in this case FKBP), signal
transduction was rendered absolutely dependent on the
bivalent drug [2]. This demonstrated the use of CID as a
method to regulate signal transduction.
Regulation of eukaryotic transcription has also been shown
by use of several different chemical dimerizers and fusion
protein pairs. Because eukaryotic transcription factors are
modular in nature, the DNA-binding and activation
domains can be expressed as separate proteins, and, as
long as they are brought in close proximity to one another,
will reconstitute sequence-specific transcriptional activa-
tion [12]. Dimerizer-dependent transcriptional regulation
has been demonstrated using various different dimerizers
and transcription-factor domains fused to FKBP. Using the
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Table 1
Chemically induced dimerization systems.
Target protein(s)* Dimerizer ligand References
FKBP FKBP FK1012 [2,7]
FKBP CNA FK506 [7]
FKBP CyP FK506–CsA [8]
FKBP FRB Rapamycin [7,9]
GyrB GyrB Coumermycin [10]
DHFR DHFR BisMTX This study
*Only the fragment of the fusion protein(s) that binds the dimerizer
ligand is listed. FKBP, FK506-binding-protein 12; CNA, calcineurin A;
CsA, cyclosporin A; CyP, cyclophilin; FRB, FKBP-rapamycin binding
domain of FKBP-rapamycin-associated protein; GyrB, B subunit of
bacterial DNA gyrase.
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semisynthetic homobifunctional dimerizer FK1012, Ho
et al. [7] showed dimerizer-dependent activation of tran-
scription in cells expressing the yeast GAL4 DNA-binding
domain and the herpes simplex virus (HSV) VP16 activa-
tion domain, each fused to multiple copies of FKBP [12].
Belshaw et al. [8] showed that the semisynthetic heterobi-
functional dimerizer FK506-cyclosporin A could be used to
regulate transcription using the fusion protein
FKBP–GAL4 DNA-binding domain and cyclophilin–VP16
activation domain. The naturally occurring rapamycin is
also an effective dimerizer. Rivera et al. [9] demonstrated
rapamycin-dependent regulation of transcription by use of
transcription factors fused to FKBP and FRB (FKBP-
rapamycin binding domain of FKBP-rapamycin-associated
protein). The DNA-binding domain was based on ZFHD1
[13], the activation domain on the carboxy-terminal region
of the NF-κB p65 protein [14]. Activation of the Raf-1
serine/threonine kinase cascade by coumermycin-induced
dimerization was demonstrated by Farrar et al. [10]. The
natural homobifunctional dimerizer can bring about the
dimerization of proteins fused to the amino-terminal sub-
domain of the B subunit of bacterial DNA gyrase, the
binding target of coumermycin. In all cases, the use of
dimerizers allows these activities to be promoted at will
and in a dose-dependent and reversible way, suggesting
various experimental and therapeutic applications [1]. For
the researcher, use of dimerizers provides a powerful
means with which to study the function of a gene by allow-
ing the consequences of its regulated expression to be ana-
lyzed both in vitro and in vivo [11]. For the clinician, the
ability to exert pharmacologic control over the expression
of a therapeutic gene, in the context of gene therapy,
would allow the timing of delivery and the dosage of gene
product to be optimized [11].
Because there are currently few protein dimerizer systems
(Table 1), additional protein–ligand pairs would be useful.
An ideal CID pair would include a well-characterized
protein, a ligand that is chemically malleable but metabol-
ically stable, and a specific, well-characterized interaction
between the two. Dihydrofolate reductase (DHFR) and
methotrexate (MTX) have these characteristics. DHFR
catalyses the NADPH-dependent reduction of dihydrofo-
late to tetrahydrofolate, which is then used directly or con-
verted to other reduced folates. DHFRs have been
characterized from various sources ranging from bacteria to
humans. Most forms, including the Escherichia coli and
mammalian enzymes, function as monomers [15,16].
Many crystallographic and nuclear magnetic resonance
(NMR) structures are available, with DHFR from numer-
ous sources bound to a wide variety of ligands. Because
DHFR is involved in thymidine biosynthesis, it has been
used extensively as a drug target for the treatment of
various forms of cancer, rheumatic diseases and bacterial
infections [17]. MTX is a folate analog that binds DHFR
very tightly and the Kd for the interaction with E. coli
DHFR is ~0.6 nM [18]. Since its synthesis in the late
1940s, MTX has been thoroughly characterized and many
analogs synthesized [19–22]. The three-dimensional struc-
ture of the binary E. coli DHFR–MTX complex has been
determined to 1.7 Å resolution [23,24].
Here, we describe the synthesis of a homobifunctional
version of MTX (bisMTX) and show that it can induce
dimerization of E. coli DHFR (Figure 1). Further, the
ternary complex formed between bisMTX and DHFR is
shown to be more stable than the binary complex
between MTX and DHFR. This suggests a dimerizer-
induced affinity modulation [25], in which an increase in
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Figure 1
Model of bisMTX-inducible DHFR
dimerization. (a) In the absence of dimerizer,
the proteins (E. coli DHFR) remain monomeric.
(b) In the presence of dimerizer (bisMTX), the
molecules of DHFR can bind the ligand to
form binary and ternary complexes.
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the affinity of the binding event is observed owing to the
generation of additional protein–protein interactions
outside of the ligand-binding sites.
Results and discussion
Dimerizer synthesis and bioavailability
The central issue in design of a dimerizer is the availability
of a site on the ligand that can be derivatized without
decreasing affinity for the target. In the case of MTX, the
glutamate-γ-carboxyl (Figure 2a) meets this criterion
readily, because wide structural variety is tolerated in
amide derivatives of this group [19,26–29]. A second impor-
tant element is the linker; although many factors, some
quite subtle, can be important [30], here a simple analysis
provided a satisfactory result. Commercial methotrexate
agarose (Sigma) uses an eight-atom spacer; we reasoned
that a chain approximately twice as long would assure ade-
quate separation, and that oxygenation would decrease
hydrophobicity and increase water solubility. DDD
(4,9-dioxa-1,12-dodecanediamine; 14 atoms) is a commer-
cially available diamine meeting both requirements.
Synthesis of the dimerizer required three steps from com-
mercial materials (Figure 2b). MTX, protected as its
α-benzyl ester (MTXBn), was prepared by coupling of
4-amino-4-deoxy-N10-methylpteroic acid (APA–OH) to
L-glutamic acid α-benzyl ester by use of a slight variation
of the procedure of Nagy et al. [31]. The α-protected
MTXBn was then doubly coupled to DDD with benzotria-
zol-1-yloxytris(pyrrolidino)phosphonium hexafluorophos-
phate (PyBOP) and deprotected by alkaline hydrolysis to
afford bisMTX in ~50% overall yield. All intermediates
and the final product were purified by reverse-phase (C18)
high-performance liquid chromatography (HPLC) and
characterized by NMR (1H and 13C) and fast atom bom-
bardment mass spectrometry (FAB–MS).
BisMTX inhibited the growth of E. coli tolC, a strain that is
sensitive to growth inhibition by methotrexate (S.J.K. et al.,
unpublished observations), indicating that the molecule
can cross biological membranes and bind E. coli DHFR
in vivo. 
Dimerized complex detected by gel filtration
To determine whether dimerization of purified DHFR
molecules could be induced by the presence of bisMTX
in vitro, we prepared a series of samples containing either
protein only (Figure 3a) or protein plus increasing concen-
trations of dimerizer drug (Figure 3b–e). The mixtures
were allowed to reach equilibrium by incubation at 25°C
for at least 12 hours, and they were then fractionated on a
Superdex 75 gel filtration column. In the absence of drug,
a single peak was observed corresponding to a molecular
weight of 17 kDa (Figure 3a), which is consistent with this
peak being monomeric DHFR (17.68 kDa [16]). In the
presence of dimerizer, a second peak corresponding to a
molecular weight of 34–35 kDa was observed
(Figure 3b–e). The higher molecular weight peak corre-
sponds to the expected size of a ternary complex consist-
ing of two molecules of DHFR tethered together by one
molecule of bisMTX. Furthermore, the generation of the
ternary peak coincided with a decrease in the intensity of
the monomer peak, which supports the interpretation that
this new peak was the product of a successful chemically
induced dimerization event. As the concentration of drug
was increased, the amount of ternary complex increased
and the amount of monomer decreased (Figure 3a–e).
In a noncooperative binding model in which each end of
the dimerizer binds independently to the protein, addition
of an increasing amount of dimerizer should increase the
fraction of protein in the ternary complex up to the stoi-
chiometric dimerizer to protein ratio of 1 to 2. Excess drug
would drive equilibrium back toward the binary complex.
The fraction of protein expected to be in the ternary
complex can be calculated on the basis of a noncoopera-
tive binding model from the published value for the
binding of MTX to E. coli DHFR (590 pM) [18]) as an
approximation for the binding of the bisMTX to DHFR
(solid lines in Figure 4). As the bisMTX:DHFR ratio is
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Figure 2
Synthesis and molecular structure of bisMTX.
(a) Structure of MTX and APA-OH.
(b) Synthesis of bisMTX. APA-OH, 4-amino-
4-deoxy-N10-methylpteroic acid; Bn, benzyl;
bisMTX, γ,γ′-DDD-linked methotrexate dimer;
bisMTXBn, γ,γ′-DDD-linked methotrexate dimer
di-α-benzyl ester; DDD, 4,9-dioxa-
1,12-dodecanediamine; DMSO, dimethyl
sulfoxide; MeOH, methanol; MTX,
methotrexate; NMP, N-methylpyrrolidinone;
PyBOP, benzotriazol-
1-yloxytris(pyrrolidino)phosphonium
hexafluorophosphate.
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increased, the fraction of protein in the ternary complex
would increase to a maximum at a bisMTX:DHFR ratio of
0.5. As the bisMTX:DHFR ratio increased further, the
fraction of protein in the ternary complex would decrease.
The shape of this curve is fairly insensitive to the value
used for the binding constant (not shown) as long as the
dissociation constant is below the total concentration of
protein used in the modeling (1 µM).
At bisMTX:DHFR ratios below 0.5, the experimental data
fit the noncooperative binding model well. However, at
concentrations of dimerizer equal to or greater than the
concentration of the protein, virtually all of the protein
remained in the ternary form. This finding is not consistent
with a simple noncooperative binding model in which, as
the concentration of dimerizer exceeds half the concentra-
tion of protein, the proportion of ternary complexes at equi-
librium would be expected to decrease (and the proportion
of binary complexes to increase). At a bisMTX:DHFR ratio
of 50, only 4% of the protein would be predicted to be in
ternary complexes, with the rest of the DHFR molecules
bound to dimerizer in a 1:1 ratio. In fact, we found that vir-
tually all of the protein was in the ternary complex at this
ratio of drug to protein (Figures 3e and 4).
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Figure 3
Gel-filtration analysis showing bisMTX-
dependent dimerization of DHFR. Samples
consisting of purified DHFR (1 µM final
concentration) with increasing concentrations
of bisMTX in final concentrations of (a) 0 µM,
(b) 0.125 µM, (c) 0.25 µM, (d) 0.50 µM and
(e) 50 µM were injected onto a Superdex 75
gel filtration column and chromatographed
with the ÄKTA purifier system. Protein
elution profiles (monitored at 280 nm) are
shown. At 0 µM bisMTX (a), the fraction of
total protein in the ternary complex is 0%. The
fraction of total protein in the ternary complex
was calculated to be (b) 32.5%, (c) 54.7%,
(d) 85%, and (e) 88.8%. The observed
molecular sizes were determined by
comparison with a set of molecular standards:
aprotinin (6.5 kDa), cytochrome c (12.4 kDa),
carbonic anhydrase (29 kDa), albumin
(66 kDa), and blue dextran (2 MDa).
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Our data fit better with a model in which formation of the
ternary bisMTX:DHFR2 complex is cooperative, (i.e.
DHFR has a higher affinity for the binary complex than
for the free drug; dashed lines in Figure 4). Note that the
predictions of the cooperative and noncooperative models
are indistinguishable at low bisMTX:DHFR ratios
(Figure 4, inset). As the cooperativity constant increases,
the ternary complexes disappear more slowly with increas-
ing concentrations of the drug (data not shown).
Cooperative binding could occur if formation of the
ternary complex involves additional interactions outside
the ligand binding sites on the DHFR molecules. This
situation would be analogous to the ‘affinity modulation’
observed by Briesewitz et al. [25]; binding of the heterobi-
functional ligand FKpYEEI (consisting of an SH2-
binding peptide linked to FK506) to the Fyn SH2
domain was increased in the presence of FKBP52 but not
FKBP12. The specificity for FKBP52 suggested that the
increase in affinity for the Fyn SH2 domain was due to
favorable protein–protein interactions involving the
surface of FKBP52.
Additional protein–protein contacts in the ternary
complex should stabilize it by decreasing the dissociation
rate. To address this possibility, the off-rate of the ligand
was investigated by a competition assay using MTX. By
gel filtration, bisMTX:DHFR2 ternary complexes were
purified and mixed with 800-fold molar excess of MTX
over protein. At timed intervals from mixing, aliquots of
the mixture were fractionated by gel filtration and the
amount of ternary complex remaining measured. A plot of
fraction ternary complex versus time fitted a first-order
exponential decay process and yielded a calculated koff of
0.0002 s–1 (Figure 5). This off-rate is ~100 times slower
than the reported value of 0.0190 s–1 for DHFR–MTX
[18]. In addition, the half-life of the complexes is longer
than the elution time of the ternary complex from the gel
filtration column; thus the column should provide a good
estimate of the species present in the mixture.
The E. coli DHFR–MTX binary complex crystallizes with
two molecules per unit cell and it is interesting to note
that the MTX-binding sites of the two DHFR molecules
face each other [23,24]. Although this was not part of our
design of bisMTX, binding of the dimerizer could poten-
tially achieve affinity modulation by recruiting the interac-
tions that form crystal contacts between monomers. The
additional stability could also result from favorable con-
tacts between bisMTX and DHFR that are not present in
the complex between MTX and DHFR. For example,
contacts with the flexible DDD linker might be entropi-
cally unfavorable in the binary complex. However, once
the conformation of the linker has been constrained in the
binary complex, structurally similar contacts in the ternary
complex might be favorable.
These two possibilities are obviously not mutually
exclusive; the extra stability, which corresponds to only a
few kilocalories of binding energy, could be due to a
combination of protein–protein and protein–drug inter-
actions. However the phenomenon arises, the stability of
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Figure 4
The fraction of protein in the ternary complex is
shown as a function of the ratio of dimerizer
(bisMTX) to protein (DHFR). Solid circles
indicate data derived from integration of the
ternary complex peaks shown in Figure 3. The
solid line shows the calculated curve for a
noncooperative binding model where
Ka = 1.69 × 109 and Kcoop = 1. The dashed line
shows the calculated curve for a cooperative
binding model where Ka = 1.69 × 109 and
Kcoop = 200. The inset focuses on the fraction
ternary complex at low drug to protein ratios.
See the Materials and methods section for
binding model calculations.
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the ternary complex in the presence of excess ligand
should be useful for the application of this CID system
to the creation of new molecular switches in vivo, where
maintaining a precise ratio of drug to protein is con-
founded by bioavailability.
Our results led us to examine the literature on other CID
systems to see whether this serendipitous affinity modu-
lation is widespread. In vivo, reversibility of ternary
complex formation has been observed at high concentra-
tions of dimerizer [10]. However, in many cases the mea-
sured response does not decrease at higher concentrations
of the dimerizer [2,7,9]. Although this finding could be
interpreted as showing cooperativity, several factors con-
found the interpretation of in vivo data including nonlin-
earity of the assays, buffering of the free dimerizer
concentration by endogenous proteins, and uncertainty
about the intracellular concentrations of both the drug
and the target protein.
Significance
We synthesized a novel bifunctional compound, bisMTX
(γ,γ′-4,9-dioxa-1,12-dodecanediamine-linked methotrex-
ate dimer) to drive the chemically induced dimerization
(CID) of dihydrofolate reductase (DHFR). The ability
of this dimerizer compound to drive the assembly of
monomeric DHFR into the bisMTX:DHFR2 ternary
complex was shown in vitro by use of the Escherichia coli
DHFR. The homobifunctional ligand binds more tightly
to its protein target than would be expected from a non-
cooperative binding model, possibly by forming novel
protein–protein interactions between the DHFR mol-
ecules in the ternary complex. The combination of
bisMTX and DHFR can be used as an additional CID
system in the design of artificial gene regulatory cir-
cuitry. The insensitivity of ternary complexes to drug
concentration should be useful for applications of this
CID system in vivo, where a plateau in the dose-
response curve may be beneficial.
Materials and methods
Materials
APA–OH hemihydrochloride dihydrate was purchased from Sigma;
PyBop, 1-hydroxybenzotriazole (HOBT), N-methylpyrrolidinone (NMP),
N,N-diisoproylethylamine (DIEA), and L-glutamic acid α-benzyl ester (H-
Glu-OBn) were purchased from Advanced ChemTech; DDD was pur-
chased from Aldrich.
General methods
Reverse-phase HPLC was performed with binary gradients formed
(except where indicated) from solvent A (water + 0.1% v/v trifluoro-
acetic acid; TFA) and solvent B (acetonitrile + 0.08% v/v TFA) and use
of absorbance detection at the indicated wavelengths. Analytical HPLC
was performed with a Waters Symmetry C18 column (4.6 × 100 mm) at
a flow rate of 1 ml/min, and preparative HPLC was performed with a
Waters Delta-Pak C18 radial compression column (100 Å pore size,
25 × 100 mm) at a flow of 10 ml/min. Except for the final step, reaction
yields are uncorrected for residual solvent, moisture and TFA. 1H-NMR
(300 MHz) and 13C-NMR (75.4 MHz) spectra were recorded in
CD3OD (deuterated methanol) and referenced to solvent peaks
(HCD2OD = 3.30 ppm or CD3OD = 49.0 ppm).
MTX α-benzyl ester (MTXBn)
A slight variation of the procedure of Nagy et al. [31] for the coupling
of APA–OH was used. APA–OH hemihydrochloride dihydrate
(102 mg, 29 µmol) and DIEA (76 µl, 43 µmol) were dissolved in
870 µl dimethyl sulfoxide (DMSO). PyBOP [32] (166 mg, 32 µmol)
was added, and the reaction was stirred at room temperature for
30 min. To this solution was added 870 µl of the mixture obtained by
combining H-Glu-OBn (151 mg, 64 µmol) with finely pulverized
K2CO3 (44 mg, 32 µmol) in 1.74 ml DMSO and sonicating for several
minutes at 50°C. The reaction mixture was agitated at 50°C until a
clear, yellow solution was obtained (about 5 min) and then stirred at
room temperature for 3 h, at which time it was diluted with 1 M
aqueous TFA (1 ml), acetonitrile (2 ml), and water (to a volume of
10 ml). The product was purified by preparative HPLC (detection by
A400) with a two-segment linear gradient (min/%B): 0/0, 5/25, 30/35.
Lyophilization of the product peak afforded 140 mg (89%) of MTXBn.
FAB–MS (thioglycerol/NaI), m/z calculated for C27H28N8O5, 544.570;
found, 545 ([M+H]+). 1H-NMR: δ 2.00–2.15 (m, 1H), 2.18–2.31 (m,
1H), 2.42 (t, 2H, J = 7.2 Hz), 3.24 (s, 3H), 4.53 (dd, 1H, J = 5.4,
9.3 Hz), 4.92 (s, 2H), 5.15 (s, 2H), 6.81 (d, 2H, J = 9.3 Hz),
7.22–7.36 (m, 5H), 7.72 (d, 2H, J = 9.0 Hz), 8.60 (s, 1H). 13C-NMR: δ
27.38, 31.36, 39.72, 54.03, 56.57, 67.92, 112.68, 122.63, 123.30,
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Figure 5
Dissociation of the ternary complex. Ternary complexes were formed
by incubation of DHFR (25 µM) and bisMTX (12.5 µM) at 25.5°C for
12 h and purified by gel filtration. The purified complexes were
combined with an 800-fold molar excess of MTX (10 mM; time 0). At
timed intervals, aliquots (1000 µl) of the ternary complex/MTX
sample were fractionated by gel filtration as in the experiments
shown in Figure 3. The amount of ternary complex present was
calculated by integration of the area under the peak corresponding
to the ternary complex. The ternary complex as a fraction of total
DHFR was plotted versus time and the data fitted to the first-order
exponential equation T = T0 e–kt, where T is the fraction of DHFR
in the ternary complex, T0 is the fraction of DHFR in the ternary
complex at time zero, and k is a first-order rate constant. The half-
life and apparent off-rate were calculated to be 55 min and
0.0002 s—1, respectively.
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129.10, 129.22, 129.50, 130.28, 37.22, 147.07, 150.35, 152.94,
153.56, 157.93, 164.86, 170.29, 173.46, 176.52.
MTX dimer di-α-benzyl ester (bisMTXBn)
Control of stoichiometry in the coupling is important, but the presence
of residual moisture and acid in the MTXBn led to uncertainty in its
quantification by mass. Therefore, the optimum stoichiometry was
determined empirically. Thus, MTXBn (67 mg, 123 µmol nominal) was
dissolved in 600 µl NMP, to which was added 147 µl (74 µmol,
0.6 equivalents) HOBT (0.5 M in NMP) followed by PyBOP (71 mg,
136 µmol, 1.1 equivalents). After 20 min, the diamine (11 µl, 51 µmol,
0.42 equivalents) was added with mixing, and the reaction was allowed
to stand for 2 h. Analytical HPLC (A330, 0–50% B over 10 min) of the
reaction showed a 3:5 area ratio of monoacylated product to the later-
eluting diacylated product, indicating the need for 25% more MTXBn.
Accordingly, an additional 17 mg (31 µmol) of MTXBn was dissolved in
75 µl NMP, to which was added 37 µl (18 µmol) HOBT (0.5 M in
NMP), 11 µl (63 µmol) DIEA, and 20 mg PyBOP. After 20 min, the
bolus was added to the main reaction, and the mixture was allowed to
stand for 3 h, at which time reaction was complete as judged by HPLC.
The reaction was quenched by the addition of DDD (2 µl) followed
after 30 min by 1 M TFA (100 µl), and then diluted with water (10 ml)
resulting in precipitation of the product. After addition of just enough
20% acetonitrile in 0.1% aqueous TFA to redissolve the product
(~150 ml), the product was purified by preparative HPLC (detection by
A400) with a two-step gradient (min/%B): 0/0, 2/30, 42/50. Lyophiliza-
tion afforded 89 mg (115% yield) of the product. The excess mass
included some tripyrrolidino phosphine oxide, a byproduct of the
PyBOP coupling. Because this compound is inert, it was not removed
before the next reaction; for the analytical sample, it was removed by
chromatographing the product on silica gel with 5:1
chloroform/methanol as the eluent. FAB-MS (thioglycerol/NaI): m/z cal-
culated for C64H76N18O10, 1256.599; found, 1279 ([M+Na]+).
1H-NMR: δ 1.47–1.55 (m, 4H), 1.66 (p, 4H, J = 6.4 Hz), 2.01–2.16 (m,
2H), 2.17–2.30 (m, 2H), 2.33 (br t, 4H, J = 6.6 Hz), 3.19 (dt, 4H,
J = 2.6, 6.8 Hz), 3.26 (s, 6H), 3.30–3.39 (m, 8H), 4.57 (dd, 2H,
J = 4.6, 9.4 Hz), 4.90 (s, 4H), 5.14 (s, 4H), 6.82 (d, 4H, J = 9.0 Hz),
7.24–7.75 (m, 10H), 7.74 (d, 4H, J = 9.0 Hz), 8.62 (s, 2H).
13C-NMR: δ 27.45, 28.05, 30.54, 33.51, 38.13, 39.94, 54.44, 56.72,
68.04, 69.54, 71.86, 112.82, 122.71, 123.45, 129.23, 129.38,
129.68, 130.46, 137.39, 147.02, 150.50, 153.05, 153.79, 157.91,
165.00, 170.20, 173.59, 174.99.
BisMTX
A solution of 43 mg (34 µmol) bisMTXBn was dissolved in 0.5 ml of
methanol and diluted with 0.5 ml of water. This solution was added
dropwise to 4 ml of a well-stirred solution of LiOH (0.5 M) in 50% (v/v)
methanol/water such that the solution remained homogeneous. After
3 h, the reaction was quenched with 5 ml 0.1 M aqueous TFA and
diluted with 50 ml 20% acetonitrile in 0.1% aqueous TFA. The product
was purified by preparative HPLC (detection by A400) using a two-
segment gradient as follows (min/%B): 0/0, 2/10, 32/40. The product
was lyophilized and desalted by repeating the HPLC with 0.2%
CH3CO2H (pH adjusted to 4.0 with NH4OH) and CH3CN, respec-
tively, as the A and B mobile phase components. Lyophilization
afforded 53 mg of a yellow solid, which was dissolved in 2 ml of water
by the addition of 75 µl 1 M NaOH to give a homogeneous solution at
pH 8. The concentration of this stock solution was determined spec-
trophotometrically by diluting a 1 µl aliquot in 1 ml 10 mM sodium-
phosphate (pH 7.4); ε309 was taken as 47,400 M–1cm–1 (twice the
value of ε304 = 23,700 reported for a MTX γ-amide at this pH [22]). The
reaction yield based on spectrophotometry was 49%. To verify that no
epimerization at glutamate Hα had occurred, an analogous reaction
was done with LiOD in methanol-d4/D2O; no loss of the glutamate Hα
signal (δ 4.53 ppm) was observed in the 1H NMR spectrum of the
product, confirming that no racemization occurred. FAB-MS (thiogly-
cerol/NaI): m/z calculated for C50H64N18O10, 1076.505; found, 1078
(8%, [M+H]+), 1100 (15%, [M+Na]+), 1122 (8%, [M+2Na–H]+), 1144
(16%, [M+3Na–2H]+). 1H-NMR: δ 1.45–1.55 (m, 4H), 1.67 (p, 4H,
J = 6.5 Hz), 2.00–2.18 (m, 2H), 2.18–2.46 (m, 6H), 3.20 (dt, 4H,
J = 2.5, 6.9 Hz), 3.24 (s, 6H), 3.28–3.45 (m, 8H), 4.53 (dd, 2H,
J = 4.6, 9.1 Hz), 4.91 (s, 4H), 6.79 (d, 4H, J = 9.0 Hz), 7.72 (d, 4H,
J = 9.0 Hz), 8.59 (s, 2H). 13C-NMR: δ 27.45, 28.27, 30.37, 33.54,
37.96, 39.77, 53.98, 56.58, 69.38, 71.71, 112.62, 122.63, 123.32,
130.25, 147.00, 150.29, 152.82, 153.56, 157.84, 164.83, 169.89,
175.06, 175.44.
Expression and purification of E. coli DHFR
A plasmid encoding E. coli DHFR (pMONDHFR; gift of Carl Frieden)
was transformed into the E. coli strain BL21DE3 to yield JH710. DHFR
was expressed and purified essentially as previously described [16,33]
except with the noted modifications. JH710 was streak-isolated from
frozen stock on LB (Luria-Bertani) plates that contained ampicillin
(200 µg/ml). An isolated colony was used to inoculate 10 ml LB broth
that contained ampicillin (200 µg/ml). This seed culture was grown at
37°C in a roller drum to yield a saturated culture. The seed culture was
used to inoculate 1 l LB broth in a 2.8 l Buchner flask, and then grown
at 37°C with shaking until an A600 of about 0.5 was reached. Isopropyl-β-D-thiogalactopyranoside (IPTG) was then added to a final concentra-
tion of 1 mM to induce transcription of the recombinant DHFR gene
from the T7 promoter. The induced culture was left to grow at 37°C
with shaking for an additional 3 h at which time the cells were har-
vested. Cells were pelleted at 6500 g for 30 min at 4°C in a Beckman
model JA-10 rotor and then resuspended in ice-cold buffer 1 (40 mM
Tris-HCl,pH 8.0 at 4°C, 20 mM EDTA, 1 mM dithiothreitol). The cells
were lysed using a French press cylinder at 10,000 psi for 30 s and the
cellular debris was pelleted at 15,000 g for 30 min at 4°C in a
Beckman JA-20 rotor. The pellet was then washed using 5 ml buffer 1
and centrifuged as above. The supernatants were combined and poly-
ethylenimine was added to a final concentration of 0.25% v/v. The
mixture was stirred at 4°C for 5 min, then centrifuged at 12,100 g for
30 min at 4°C using a Beckman JA-20 rotor. The supernatants were
combined, and protein precipitated by the addition of ammonium
sulfate to a final concentration of 40% w/v. The mixture was stirred at
4°C for at least 2 h (up to 72 h) and protein pelleted by centrifugation
at 12,100 g for 15 min at 4°C using a Beckman JA-20 rotor. Pelleted
protein was discarded, and the protein remaining in the supernatant
was further purified by affinity chromatography.
The protein (~50 ml) was loaded onto a 25 ml MTX-agarose affinity
column that had been equilibrated in LS buffer (40 mM potassium
phosphate, pH 6.0 at 4°C, 200 mM KCl, 2 mM EDTA, 1 mM dithiothre-
itol), and run at 1 ml/min using the ÄKTA purifier system (Pharmacia).
The column was washed using two column volumes of HS buffer
(200 mM potassium phosphate, pH 6.0 at 4°C, 1 M KCl, 2 mM EDTA,
1 mM dithiothreitol). Retained protein was eluted from the column by
the addition of elution buffer (200 mM potassium phosphate, pH 8.0 at
4°C, 1 M KCl, 2 mM EDTA, 1 mM dithiothreitol) that contained 2 mM
folic acid. Eluted column fractions were monitored at 280 nm and ana-
lyzed for protein content by SDS–PAGE. The fractions containing
DHFR were pooled, diluted 10-fold with P500 buffer (50 mM potas-
sium phosphate, pH 7.0 at 4°C, 500 mM NaCl, 1 mM EDTA), then
diafiltered using an Amicon (Beverley, MA) stirred cell equipped with a
YM10 membrane. This diafiltration cycle was performed four times in
total to remove any remaining folic acid (detection by A350). Equal
weights of activated charcoal and protein were combined and gently
stirred for 10 min at 4°C. The supernatant was retrieved by centrifuga-
tion and then filtered through a 0.45 µm filter. This treatment was per-
formed three times in total to remove any contaminating NADPH
(detection by A340). The protein preparation was then further purified
by gel filtration with a Superdex 75 HR 10/30 FPLC column (Pharma-
cia) with a bed volume of 24 ml. The fractions containing DHFR were
pooled, and glycerol was added to a final concentration of 25% v/v. A
sample of the final protein preparation was analyzed by SDS–PAGE
and found to be greater than 95% pure by Coomassie staining. The
concentration of the purified protein preparation was determined using
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the Beer–Lambert law (with ε280 calculated to be 33,710 M–1 cm–1
[34]); the final preparation was subaliquoted and stored at –80°C.
Gel filtration assay
Molecular sizes were determined by gel filtration with a Superdex 75
HR 10/30 FPLC column (Pharmacia) with a bed volume of 24 ml.
Samples (1000 µl) containing purified DHFR (1 µM) along with
increasing concentrations of bisMTX (see Figures 3 and 4 for final con-
centrations of dimerizer) were prepared with P500 buffer and allowed
to reach equilibrium by incubation at 25.5°C for at least 12 h. Controls
containing bisMTX only (up to 5 µM), MTX only (up to 40 µM), and
DHFR and MTX at a 1:2 molar ratio were prepared in the same way.
Samples were injected onto the column and chromatographed with the
ÄKTA system (Pharmacia) at 0.5 ml/min at room temperature with the
same buffer. The observed molecular sizes were determined by com-
parison with a set of molecular standards (Sigma) that consisted of
aprotinin (6.5 kDa), cytochrome c (12.4 kDa), carbonic anhydrase
(29 kDa), albumin (66 kDa), and blue dextran (2 MDa). The area under
each curve was integrated and used to calculate the fraction of protein
in the ternary complex. Column fractions were collected and further
analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS–PAGE) followed by Coomassie staining.
Modeling complex formation
Theoretical binding isotherms were generated in a Microsoft Excel
spreadsheet based on the equations:
where [P], [PD] and [P2D] are the concentrations of the free DHFR
protein, the binary complex, and the ternary complex, respectively; [D]
and Dtot are the free and total concentrations of the dimerizer drug
bisMTX, respectively; Ka is the intrinsic association constant for the
binding of the dimerizer to the protein; and Kcoop is the cooperativity
constant associated with formation of the ternary complex. A fixed
value of Ptot = 1 µM was used, [D] was varied, and all other species
were calculated. The ratio bisMTX:DHFR is Dtot/Ptot, and the fraction of
protein as ternary complex is [P2D]/Ptot. For the noncooperative model,
Kcoop = 1.
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